In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

This content is currently on FREE ACCESS, enjoy another 54 days of free consultation

In these unprecedented times, the ESC is doing everything it can to support its community: FREE access to all ESC 365 content until 31 July: explore more than 125,000 educational resources.

From 1 August onwards, support our mission by becoming a member.

Plasma proteomic profile predicts survival in heart failure with reduced ejection fraction

Session Poster Session 7

Speaker David Lanfear

Event : ESC Congress 2019

  • Topic : heart failure
  • Sub-topic : Chronic Heart Failure - Diagnostic Methods: Biomarkers
  • Session type : Poster Session

Authors : H Gui (Detroit,US), RC She (Detroit,US), JIA Li (Detroit,US), HANI N Sabbah (Detroit,US), L K Williams (Detroit,US), DAVID Lanfear (Detroit,US)

H Gui1 , RC She1 , JIA Li1 , HANI N Sabbah1 , L K Williams1 , DAVID Lanfear1 , 1Henry Ford Hospital - Detroit - United States of America ,


Background: Whether the plasma proteome can predict the course of heart failure (HF) and has incremental value to established predictors is uncertain. Methods: Patients meeting Framingham HF criteria with history of reduced ejection fraction (n=1017) were prospectively enrolled in a registry and donated fasting blood samples.  Plasma underwent analysis on the SOMAscan proteomic discovery platform, quantifying 4789 proteins using standard assay and quality controls. Patients were randomly divided into derivation (n=681) and validation (n=336) cohorts.  We derived a proteomic risk score (PRS) in the derivation cohort using Lasso-penalized Cox regression and then tested it in the validation cohort. Both models were adjusted for an establish HF clinical risk score (MAGGIC) and NTproBNP.  We assessed risk stratification improvement in the validation cohort by comparing models with and without PRS using the model C statistic, continuous net reclassification index (NRI), integrated discrimination index (IDI), and the median improvement in risk score (MIRS).  Results: Overall 47.5% of patients were African American, 35.2% were female, mean ejection fraction was 34.8%, and average age was 67.9 years. After median follow-up of 3.6 years, there were 296 deaths (194 in derivation and 102 in validation).  Optimized modeling defined a 32 protein PRS (hazard ratio [HR] 2.33, p<2.00E-16) which was also statistically significant when tested in the validation cohort (PRS HR=1.19, p=4.87E-02) and showed some improvement in risk stratification (Table).  Conclusion: A plasma multi-protein predictive score can improve risk stratification in HF patients on top of a validated clinical score and NTproBNP.  Additional investigation is warranted to define mechanisms underlying individual proteins and explore proteomic clinical applications.

Methods Variables Estimate 95% CI P
Validation Testing
MAGGIC 1.06 1.027, 1.092 2.84E-04
NTproBNP 1.84 1.430, 2.359 1.88E-06
PRS 1.19 1.001, 1.408 4.87E-02
Risk Stratification Assessment
C-statistic improvement 0.012 -0.076, 0.101 8.30E-01
IDI 0.034 0.007, 0.095 <2.00E-16
continuous-NRI 0.286 -0.062, 0.475 9.00E-02
Median Improvement in Risk Score 0.015 0.001, 0.078 2.00E-02

Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are